Ami Fadia

Needham | Healthcare

Ami Fadia is an analyst from Needham specializing in the Healthcare sector. Ranked #559 out of 4773 analysts, they have issued 67 stock ratings with a success rate of 90.81% and an average return of 37.85%.

Ami Fadia has a well-established track record, with 67 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 90.81% and an average return of 37.85%, underscoring their expertise and ability to identify winning opportunities for investors.

#559

Out of 4773

67

Total Ratings

+90.81%

Success Rate

+37.85%

Average Return

Recent Ratings Analysis

HRMY

Aug 04, 2026

Target

$50.00

Current

$41.52

Performance

7.07%

Ami Fadia rated HRMY as Buy on Aug 04, 2026, setting a price target of 50. The call has proven timely, with shares rising 7.07% toward the price target of 50.

JAZZ

Aug 04, 2026

Target

$292.00

Current

$245.80

Performance

-6.05%

On Aug 04, 2026, JAZZ was given a Buy rating by Ami Fadia, with a target price of 292. Despite the Buy call, shares fell from 245.8 to 245.8, challenging the optimistic stance.

NBIX

Jul 31, 2026

Target

$204.00

Current

$156.22

Performance

-6.34%

NBIX received a Buy rating from Ami Fadia on Jul 31, 2026, aiming for 204. The rating hasn’t played out as hoped, with the stock trading 6.34% below expectations.

BCYC

Jul 30, 2026

Target

$14.00

Current

$3.86

Performance

-3.74%

On Jul 30, 2026, Ami Fadia published a Buy outlook on BCYC, with a target of 14. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 3.86.

IMRX

Jul 20, 2026

Target

$18.00

Current

$4.27

Performance

-0.47%

Ami Fadia on Jul 20, 2026 assigned IMRX a Buy rating, with a price target of 18. The recommendation remains pending validation as shares consolidate around 4.27.

RVMD

Jul 20, 2026

Target

$236.00

Current

$203.77

Performance

12.96%

On Jul 20, 2026, Ami Fadia reaffirmed RVMD with a Buy rating, targeting 236. The recommendation was supported by strong follow-through as the stock rose from 203.77 to 203.77.

ALKS

Jul 13, 2026

Target

$62.00

Current

$45.97

Performance

-11.37%

ALKS was rated Buy by Ami Fadia on Jul 13, 2026, with a price objective of 62. This case shows how bullish projections can fail, with the stock now below 45.97.

MPLT

Jul 10, 2026

Target

$45.00

Current

$13.00

Performance

-66.94%

On Jul 10, 2026, Ami Fadia initiated coverage on MPLT with a Buy rating and target of 45. The Buy call has yet to be validated as shares remain 32.00 away from the target.

BIIB

Jun 29, 2026

Target

$256.00

Current

$217.15

Performance

0.24%

Ami Fadia issued a Buy recommendation for BIIB on Jun 29, 2026, price target set at 256. The target of 256 remains in play, though confirmation will depend on future moves.

PRAX

Jun 29, 2026

Target

$575.00

Current

$334.58

Performance

-4.56%

On Jun 29, 2026, PRAX was evaluated by Ami Fadia, who gave a Buy rating and target of 575. So far, the Buy call awaits clearer momentum, with shares flat at 334.58.

DFTX

Jun 23, 2026

Target

$50.00

Current

$38.89

Performance

7.49%

Ami Fadia rated DFTX as Buy on Jun 23, 2026, setting a price target of 50. The call has proven timely, with shares rising 7.49% toward the price target of 50.

NMRA

Jun 16, 2026

Target

$5.00

Current

$1.04

Performance

-33.33%

On Jun 16, 2026, NMRA was given a Buy rating by Ami Fadia, with a target price of 5. Despite the Buy call, shares fell from 1.04 to 1.04, challenging the optimistic stance.

AXSM

May 05, 2026

Target

$267.00

Current

$220.75

Performance

-1.04%

AXSM received a Buy rating from Ami Fadia on May 05, 2026, aiming for 267. Price action was muted, as shares hovered around 220.75 despite the bullish outlook.

ATAI

Mar 09, 2026

Target

$14.00

Current

$7.35

Performance

88.95%

On Mar 09, 2026, Ami Fadia published a Buy outlook on ATAI, with a target of 14. Shares gained 88.95%, underscoring the accuracy of the bullish outlook toward 14.

DAWN

Mar 06, 2026

Target

—

Current

$21.53

Performance

1.56%

Ami Fadia on Mar 06, 2026 assigned DAWN a Hold rating, with a price target of null. The Hold stance reflected consolidation, as shares held near 21.53.

GHRS

Mar 06, 2026

Target

$32.00

Current

$27.20

Performance

70.75%

On Mar 06, 2026, Ami Fadia reaffirmed GHRS with a Buy rating, targeting 32. The recommendation was supported by strong follow-through as the stock rose from 27.2 to 27.2.

COGT

Dec 08, 2025

Target

—

Current

$33.41

Performance

-17.10%

COGT was rated Hold by Ami Fadia on Dec 08, 2025, with a price objective of null. Investors who stayed cautious avoided some of the 17.10% decline.

ACAD

Nov 06, 2025

Target

$29.00

Current

$27.83

Performance

28.55%

On Nov 06, 2025, Ami Fadia initiated coverage on ACAD with a Buy rating and target of 29. The stock’s climb of 28.55% since the call highlights the foresight in the rating.

AVDL

Oct 22, 2025

Target

—

Current

$21.64

Performance

16.85%

Ami Fadia issued a Hold recommendation for AVDL on Oct 22, 2025, price target set at null. A neutral call gave way to stronger-than-expected performance, closing in on null.

MNMD

Oct 13, 2025

Target

$28.00

Current

$20.69

Performance

68.90%

On Oct 13, 2025, MNMD was evaluated by Ami Fadia, who gave a Buy rating and target of 28. This case illustrates how a timely bullish rating can translate into tangible gains of 68.90%.

MRUS

Sep 29, 2025

Target

$96.00

Current

$90.00

Performance

-3.92%

Ami Fadia rated MRUS as Hold on Sep 29, 2025, setting a price target of 96. The Hold stance appears justified, as shares hovered around 90 with a -3.92% move.

SAGE

Jun 16, 2025

Target

—

Current

$8.68

Performance

-4.30%

On Jun 16, 2025, SAGE was given a Hold rating by Ami Fadia, with a target price of null. Market indecision, reflected in sideways trading near 8.68, supported the cautious call.

BPMC

Apr 08, 2025

Target

$133.00

Current

$129.46

Performance

63.42%

BPMC received a Buy rating from Ami Fadia on Apr 08, 2025, aiming for 133. Momentum has favored the Buy call, with shares climbing from 129.46 to 129.46, rewarding those who trusted the recommendation.

ITCI

Feb 21, 2025

Target

—

Current

$131.87

Performance

2.54%

On Feb 21, 2025, Ami Fadia published a Hold outlook on ITCI, with a target of null. Sideways action left the Hold view intact, with no major move since 131.87.

Frequency Asked Questions

Who is Ami Fadia?

Ami Fadia is an analyst from Needham specializing in the Healthcare sector.

What is Ami Fadia's success rate?

Ami Fadia currently has a success rate of +90.81%.

How many ratings has Ami Fadia issued?

Ami Fadia has issued 67 stock ratings so far.

What is the average return of Ami Fadia's calls?

Their stock ratings have generated an average return of +37.85%.

What is Ami Fadia's ranking?

Ami Fadia is ranked #559 out of 4773 analysts.

What types of ratings does Ami Fadia give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Ami Fadia?

You can follow Ami Fadia by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Ami Fadia?

Their latest rating was a Buy on HRMY issued on 2026-08-04.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep